Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus PHENERGAN VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus PHENERGAN VC.
CETIRIZINE HYDROCHLORIDE vs PHENERGAN VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
5-10 mg orally once daily; maximum 10 mg per day.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in moderate to severe impairment).
9-16 hours; prolonged in hepatic impairment.
Primarily renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination